Mail

ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

0.5519

-0.0187 (-3.28%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	0.5706
Open	0.5800
Bid	0.5400 x 3200
Ask	0.5685 x 900
Day's Range	0.5425 - 0.5900
52 Week Range	0.2900 - 1.0600
Volume	100,188
Avg. Volume	615,377

Market Cap	37.336M
Beta (5Y Monthly)	1.77
PE Ratio (TTM)	N/A
EPS (TTM)	-0.0590
Earnings Date	Feb 10, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	1.38

All

News

Press Releases

Simply Wall St.
Have Insiders Been Buying IsoRay, Inc. (NYSEMKT:ISR) Shares This Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- Insider Buying: The FirstService Corporation (TSE:FSV) Independent Director Just Bought US$862k Worth Of Shares
  Simply Wall St.
- Have Insiders Been Buying JD Sports Fashion plc (LON:JD.) Shares?
  Simply Wall St.
Thomson Reuters StreetEvents
Edited Transcript of ISR earnings conference call or presentation 11-Feb-20 9:30pm GMT
Q2 2020 IsoRay Inc Earnings Call
Zacks
IsoRay (ISR) Upgraded to Buy: Here's What You Should Know
IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Zacks
IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -7.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Isoray Announces Second Quarter Fiscal 2020 Financial Results
Revenue Increased 16% Year-Over-YearGross Profit Increased 45% Year-Over-Year RICHLAND, Wash., Feb. 11, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology.
GlobeNewswire
Isoray Collaborates with MIM Software to Deliver an Advanced Treatment Solution for Recurrent Head and Neck Cancers
Isoray, Inc. (NYSE American: ISR) today announced an executed agreement with MIM Software to deliver a novel one-stop-provides-all program to treat head and neck cancer. The new offering bundles MIM’s software technology and Isoray’s industry leading Cesium Blu™, also known as Cesium-131, brachytherapy expanding treatment options and access for physicians and patients. Cesium Blu brachytherapy delivers a highly targeted treatment to the site of the disease, preserving healthy tissue and organs.
Zacks
IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswire
Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020
RICHLAND, Wash., Jan. 31, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.
Simply Wall St.
One Thing To Remember About The IsoRay, Inc. (NYSEMKT:ISR) Share Price
Anyone researching IsoRay, Inc. (NYSEMKT:ISR) might want to consider the historical volatility of the share price...
Simply Wall St.
If You Had Bought IsoRay (NYSEMKT:ISR) Stock Five Years Ago, You'd Be Sitting On A 63% Loss, Today
It is a pleasure to report that the IsoRay, Inc. (NYSEMKT:ISR) is up 91% in the last quarter. But that doesn't change...
Thomson Reuters StreetEvents
Edited Transcript of ISR earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q1 2020 IsoRay Inc Earnings Call
Zacks
What Makes IsoRay (ISR) a New Strong Buy Stock
IsoRay (ISR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Zacks
IsoRay (ISR) Reports Q1 Loss, Tops Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 50.00% and 4.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Isoray Announces Record First Quarter Fiscal 2020 Financial Results
Record Revenue and Gross ProfitRevenue Increased 48% Year-Over-Year RICHLAND, Wash., Nov. 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and.
Zacks
Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.
We Think IsoRay (NYSEMKT:ISR) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
GlobeNewswire
Isoray To Announce First Quarter Fiscal 2020 Financial Results on November 12, 2019
RICHLAND, Wash., Oct. 31, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.
GlobeNewswire
Isoray Will Have Prominent Role at American Brachytherapy Society’s Annual Prostate Brachytherapy Workshop
RICHLAND, Wash., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is scheduled to take place November 1-2 at the Hyatt Regency Denver at Colorado Convention Center in Denver, Colorado. The workshop’s Co-Chairmen are Dr. Brett W. Cox, Interim Chairman of the Department of Radiation Medicine at Lenox Hill Hospital and Chief of Brachytherapy for Northwell Health, and Dr. Peter J. Rossi, Calaway Young Cancer Center and Valley View Hospital.
Thomson Reuters StreetEvents
Edited Transcript of ISR earnings conference call or presentation 24-Sep-19 8:30pm GMT
Q4 2019 IsoRay Inc Earnings Call
Simply Wall St.
Breakeven On The Horizon For IsoRay, Inc. (NYSEMKT:ISR)
IsoRay, Inc.'s (NYSEMKT:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and...
Zacks
IsoRay (ISR) Reports Q4 Loss, Tops Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 5.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results
Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, Wash., Sept. 24, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical.
ACCESSWIRE
IsoRay, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / September 24, 2019 / IsoRay, Inc. (NYSEMKT: ISR ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on September 24, 2019 at 4:30 PM ...
GlobeNewswire
A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment
A recent publication is drawing attention for its positive report on a study of the ten-year findings on the impact of Cesium-131 internal radiation therapy in treating a series of cancer patients. The peer reviewed publication, Long-term Biochemical Outcomes Using Cesium-131 in Prostate Brachytherapy, was recently made available on the website of BRACHYTHERAPY, an international multidisciplinary journal. The publication reported on a study of a series of 571 patients who were treated with Cesium-131 prostate brachytherapy at the Chicago (IL) Prostate Cancer Center by radiation oncologist Dr. Brian J. Moran.
GlobeNewswire
Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019
RICHLAND, Wash., Sept. 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.